This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss
by Zacks Equity Research
Iovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022.
Moderna (MRNA) Q4 Earnings Top, COVID-19 Vaccine Brings $7B
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine sales beat expectations. The company delivers 297 million doses of its COVID-19 vaccine during the fourth quarter. Stock gains in pre-market.
The Zacks Analyst Blog Highlights Merck & Co, Shopify, Intercontinental Exchange, Barrick Gold Corp and NXP Semiconductors
by Zacks Equity Research
Merck & Co, Shopify, Intercontinental Exchange, Barrick Gold Corp and NXP Semiconductors are included in this analyst blog.
AstraZeneca (AZN) Enhertu Effective in HER2-Low Breast Cancer
by Zacks Equity Research
AstraZeneca's (AZN) DESTINY-Breast04 is the first-ever phase III study of a HER2-directed therapy to show a statistically significant and clinically meaningful survival benefit in patients with HER2-low metastatic breast cancer.
Is a Beat Likely for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the fourth-quarter earnings call that reduce its dependence on Spikevax.
Top Research Reports for Merck, Shopify & Intercontinental Exchange
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Shopify Inc. (SHOP), and Intercontinental Exchange, Inc. (ICE).
Exelixis (EXEL) Q4 Earnings & Revenues Beat, Cabometyx Strong
by Zacks Equity Research
Exelixis (EXEL) beats on both earnings and revenues in the fourth quarter. Both figures increase on a year-over-year basis.
Mirati (MRTX) Down on Longer Review Period for Adagrasib NDA
by Zacks Equity Research
The FDA accepts Mirati's (MRTX) NDA for its lung cancer candidate, adagrasib. A decision is expected by Dec 14, 2022.
Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) rides high on both earnings and sales beating estimates in the fourth quarter of 2021.
Is Invesco Defensive Equity ETF (DEF) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DEF
Is Merck & Co. (MRK) Suitable for Value Investors Now?
by Zacks Equity Research
Let's see if Merck & Co. (MRK) stock is a good choice for value-oriented investors right now from multiple angles.
Corcept's (CORT) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Corcept's (CORT) earnings beat estimates in the fourth quarter of 2021 while revenues miss the same.
Is Hartford Multifactor Developed Markets exUS ETF (RODM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RODM
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
Lilly's (LLY) COVID-19 Drug Gets FDA Nod for Emergency Use
by Zacks Equity Research
Lilly's (LLY) new antibody-drug, bebtelovimab is authorized to treat certain non-hospitalized adults and pediatric patients with mild-to-moderate COVID-19 who are at high risk of progressing to severe disease
Seagen (SGEN) Q4 Earnings Miss, Revenues Top Mark, Stock Down
by Zacks Equity Research
Seagen (SGEN) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock falls in after-hours trading.
AstraZeneca (AZN) Q4 Earnings Beat, COVID Vaccine Drives Sales
by Zacks Equity Research
AstraZeneca (AZN) surpasses fourth-quarter estimates for both revenues and earnings. The company issues 2022 guidance
NGM Bio (NGM) Up on Fast Track Tag For Ophthalmology Drug
by Zacks Equity Research
The FDA bestows a Fast Track designation to NGM Bio's (NGM) product candidate, NGM621, for treating patients with geographic atrophy secondary to age-related macular degeneration. Stock up.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
The Zacks Analyst Blog Highlights: AbbVie, Merck, Eli Lilly, Novartis and Pfizer
by Zacks Equity Research
AbbVie, Merck, Eli Lilly, Novartis and Pfizer are included in this analyst blog.
Drug/Biotech Stock Q4 Earnings Due Feb 8: PFE, INCY & DCPH
by Sundeep Ganoria
Let us take a look at three biotech/drug companies that are slated to release quarterly results on Feb 8.
Pharma Stock Roundup: MRK, LLY, ABBV Post Q4 Earnings, PFE Ends Vupanorsen Program
by Kinjel Shah
AbbVie (ABBV), Merck (MRK), Eli Lilly (LLY) and Novartis (NVS) report fourth-quarter results. Pfizer (PFE) ends vupanorsen development.
Merck (MRK) Q4 Earnings & Sales Beat, COVID Drug Adds $952M
by Zacks Equity Research
Merck (MRK) beats Q4 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.
Merck (MRK) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 23.29% and 7.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?